Schema Therapy for Patients With Chronic Treatment Resistant Depression

Aims of study:

The central aim of this study is to investigate whether Schema Therapy (ST) of longer duration (up to 30 sessions) outperforms the current treatment as usual (TAU) for patients with chronic and treatment resistant depression (CTRD) on depression outcomes at 12 months after baseline measurements, as well as at 6 and 24 months time points after baseline. It is hypothesized that the treatment effect in ST is mediated by changes in the psychological phenomenons called modes, namely Healthy Adult Mode and Vulnerable Child Mode, and that treatment effect is moderated by childhood adversity.

A second aim is to expand the understanding of what constitutes a successful therapy by investigating relevant secondary outcomes at the same time points. When dealing with chronic and/or treatment resistant illnesses, other success criteria such as level of functioning, personal recovery, or a completely different, patient-generated outcome, might be more obtainable than improvements in illness symptoms alone.

Also, it will be investigated whether schema therapy is more advantageous from a health economic aspect, both in terms of quality of life for the patient and from an economical societal perspective.

The final aim for the study is to investigate and define the population of patients with CTRD. It will be attempted to refine the Maudsley Staging Model for CTRD by including (failed) psychotherapy trials. As a part of this, it will be investigated whether patients with Treatment Resistant Depression (TRD) and Chronic Depression (CD), respectively, can be adequately understood as exhibiting similar characteristics in symptoms and response to treatments.

Background for study:

CTRD-patients seem to differ substantially from non-CTRD patients in numerous respects: factors such as adverse events in childhood, higher prevalence of comorbid personality disorders as well as inhibiting personality features, interpersonal behavior and cognitive styles.

With this knowledge, ST may be a particularly promising treatment for CTRD, as it targets both childhood adversity and particular inhibiting personality features. Going to the 'root of problems', ST can potentially have a more enduring effect on the presenting symptoms. Also, CTRD responds differently to psychotherapy than non-CTRD with smaller effects and with fewer 'sudden gains' compared to non-chronic depression. Longer duration of treatment also seems to be necessary; a meta-analysis estimated a minimum of 18 sessions necessary to produce convincing results. It is thus likely that a longer duration of ST therapy, as opposed to the shorter TAU, will still be cost-effective due to greater and/or longer-lasting effects.

Clinical practice varies widely in Denmark and internationally, and the extent to which these patients are correctly diagnosed, classified, registered and referred to specialized, prolonged CTRD treatment is unknown and probably not reflecting the true prevalence of CTRD-patients. To some extent, staging models encompass the differential features of CTRD, but even the most elaborate and validated, the Maudsley Staging Model (MSM) does not include treatment with psychotherapy as a variable. The addition of former failed psychotherapy trials could possibly improve the predictive value on factors such as dropout, short- and long-term effect of psychotherapy, and effect of differential types of psychotherapy (long duration ST vs TAU). This could provide essential information for treatment selection as well as short- and even long-term prognosis.

Study design:

This is a multi-center, two-arm, parallel group, assessor-blinded, randomized controlled superiority study. Participants will be allocated 1 : 1 to either 30 sessions of ST or to treatment as usual (TAU) for treating CTRD. Both treatment conditions will include administration of medical treatment as appropriate, following the usual treatment regimes in Danish secondary mental health services. Data will be collected via interview and self-report at baseline prior to randomization, and again at 6, 12 and 24 months after baseline measurements.

The treatment will take place at six psychiatric out-patient clinics in the Southern (Odense; Svendborg) and Capital (Copenhagen/Nørrebro, Frederiksberg (2 clinics), Ballerup) regions of Denmark.

Schema therapists:

The ST-therapists will be recruited on the basis of willingness to and availability for training. 21 therapists will be trained in order to ensure enough available therapists in the case of therapist drop-out from the study. As the risk for dropout of therapists has proven to be high, privately practicing psychologists with schema therapy and prior psychiatric experience will be employed to provide treatment as needed on the sites.

All therapists should have degrees within psychology, medicine, physiotherapy, nursing, or social work as well as prior psychotherapeutic experience. After training in ST, the therapists' competency and adherence to the treatment protocol will be evaluated, and therapists performing under the required level of competency will not be providing treatment in the study. This is done by submission of one video recorded therapy session by each therapist with a current patient at the treatment site. This patient is not part of the study intervention group, and no further data is collected on the patient. While the patient in the video will receive some sort of schema therapeutic intervention, this is thought to be within the scope of the treatment that the patient would have otherwise received in treatment at the site. The patient will be asked at the previous therapy session whether they would be willing to be video recorded at the next session for the purpose of the study. A separate information sheet will be distributed for this purpose right before the initiation of recording.

Throughout the study, therapists will receive 1,5 hours of monthly supervision in groups of up to 10 therapists. A selection of the therapy sessions for each therapist will be video-recorded and evaluated for adherence by research assistants A (after the conclusion of intake assessments) and B.

Concomitant treatment:

Psychopharmacological treatment and changes in medicine prescriptions are permitted by the psychiatrists working at the treatment sites, since this is a part of the regular depression treatment in the Danish secondary psychiatric sector. Medication use will be monitored via the electronic journal system. Concomitant psychopharmacological or psychotherapeutic treatment outside of the treatment sites is discouraged, but participants will still be included in the intent-to-treat-analyses. Concomitant treatment will be registered as part of study data.

Sample size:

Sample size planning is based on previous studies that used the short form of the Hamilton Rating Scale for Depression (HAM-D6) as their primary or secondary outcome. In previous studies, the standard deviation of HAM-D6 scores at end-of-treatment was around 3.5 within the intervention arms . A difference of 2 units on the HAM-D6 (i.e., d=0.57) is considered clinically relevant; this is the difference we would not like to miss in the comparison of the group averages at the 12 month measurement point. On the HAM-D6 scale (range 0…22), 2 units correspond to an improvement on two of the six items (depressed mood, guilt feelings, work and interest, psychomotor retardation, psychic anxiety, general somatic symptoms). At the conventional significance level of α=0.05 two-tailed, a total of N=100 participants need to be randomized to detect the relevant group difference with 80% power.

The number of randomized participants should be increased to account for clustering and dropout. The therapy is administered individually (not in groups); therefore, cluster effects are expected to be low (intra-cluster correlation = 0.01), but not zero because several participants are treated by the same therapist. Dropout is assumed to be substantial in this patient population and should be compensated in the sample size calculation even if the main analysis uses imputation of missing data.

With a cluster size of around 5 participants per therapist, and accounting for a dropout of approximately 20%, the total sample size should be increased to a total of 129 participants, randomized 1:1 in each intervention arm.

Recruitment, participant information and consent:

When referred to psychiatric treatment in the Mental Health Services, Capital and Southern Regions of Denmark, all new patients routinely go through a treatment intake interview. At this interview, the site's clinicians will also evaluate the possible participants' eligibility for the study.

Interested individuals are then contacted by the research team who will give further verbal and written information about the study by telephone and e-mail. If the participant is still interested and eligible, a minimum of 24 hours is given before the baseline interview to consider whether they would like to participate or not. The baseline assessment interview takes place in a quiet setting, either with physical presence in an office at a research or treatment site, or if preferred by the participant, online on a secure platform. Written informed consent is collected. The participants will be informed that participation is voluntary and that withdrawal from the study is possible at any time without implications for the treatment to which they were referred.

The participants do not receive any monetary or other reimbursements, gifts or rewards for their participation.

Assignment to interventions, randomization and concealment of treatment allocation:

Following screening and baseline assessment, participants will be randomized to either ST or TAU with a 1:1 allocation. The randomization was stratified by depression severity (moderate or severe; HAM-D6) and childhood maltreatment (Childhood Trauma Questionnaire (CTQ), dichotomized) at baseline for the first 14 included patients; however, this was changed to stratification for site for the remainder of included patients. The data management system Redcap (Research Electronic Data Capture), a secure web application for building and managing online surveys and databases, will execute randomization.

Adequate allocation concealment is secured by not performing the randomization until after baseline assessment and recruitment into the trial.

After randomization, the baseline assessor (Assistant A) will inform the relevant clinic about the treatment allocation. Thus, assistant A will be the only researcher knowledgeable about the results of randomization and will therefore not be involved in the outcome or follow-up assessments.

Information from the electronic patient journals:

After a participant has agreed to participate in the study, written consent will be obtained from the participant for the research team to be able to access the participant's electronic patient journals in order to obtain information about given psychotherapeutic, psychopharmacological or other psychiatric treatment before or during the trial. This information is used to be able to evaluate the participant's degree of treatment resistance and the extent of given treatment as part of the scientific evaluation in relation to the study's purpose, and further to be able to control and monitor for quality and adherence to treatment. Also, consent will be collected about being contacted in the case of treatment dropout in order to obtain information about the cause of the dropout.

Plans to promote participant retention and complete follow-up:

As a natural part of psychotherapeutic treatment, study participants who utter doubt as to whether to stay in treatment will be invited by their therapist to a collaborative and motivational inquiry about their doubts. Study participants who are absent from therapy sessions without notice will be contacted for a similar inquiry.

At the 6-, 12-, and 24

• Change from baseline in depression symptoms on the Hamilton-6 Rating Scale for Depression at 6 months after baseline measurements [Срок оценки: From baseline measurements to end of treatment (Treatment at usual) at 6 months]
• Change from baseline in depression symptoms on the Hamilton-6 Rating Scale for Depression at 24 months after baseline measurements [Срок оценки: From baseline measurements to after 24 months]
• Change from baseline in subjective functional impairment as measured on the Work and Social Adjustment Scale (WSAS) at 6 months after baseline measurements [Срок оценки: From baseline measurements to end of treatment (Treatment at usual) at 6 months]
• Change from baseline in subjective functional impairment as measured on the Work and Social Adjustment Scale (WSAS) at 12 months after baseline measurements [Срок оценки: From baseline measurements to end of treatment (of schema therapy) at 12 months]
• Change from baseline in subjective functional impairment as measured on the Work and Social Adjustment Scale (WSAS) at 24 months after baseline measurements [Срок оценки: From baseline measurements to after 24 months]
• Change from baseline in psychological well-being as measured on the WHO-5 Well-Being Index at 6 months after baseline measurements [Срок оценки: From baseline measurements to end of treatment (Treatment at usual) at 6 months]
• Change from baseline in psychological well-being as measured on the WHO-5 Well-Being Index at 12 months after baseline measurements [Срок оценки: From baseline measurements to end of treatment (Schema therapy) at 12 months]
• Change from baseline in psychological well-being as measured on the WHO-5 Well-Being Index at 24 months after baseline measurements [Срок оценки: From baseline measurements to after 24 months]
• Change from baseline in personal recovery after mental illness as measured on the INSPIRE-O Brief at 6 months after baseline measurements [Срок оценки: From baseline measurements to end of treatment (Treatment at usual) at 6 months]
• Change from baseline in personal recovery after mental illness as measured on the INSPIRE-O Brief at 12 months after baseline measurements [Срок оценки: From baseline measurements to end of treatment (Schema therapy) at 12 months]
• Change from baseline in personal recovery after mental illness as measured on the INSPIRE-O Brief at 24 months after baseline measurements [Срок оценки: From baseline measurements to after 24 months]
• Change from baseline in reactions to anger as measured on the Dimensions of Anger Reactions - Revised (DAR) at 6 months after baseline assessments [Срок оценки: From baseline measurements to end of treatment (Treatment at usual) at 6 months]